Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

DiaMedica Therapeutics (DMAC) Shares Outstanding (Weighted Average) (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Shares Outstanding (Weighted Average) readings, the most recent being $53.8 million for Q1 2026.

  • Quarterly Shares Outstanding (Weighted Average) rose 25.56% to $53.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $53.8 million through Mar 2026, up 25.56% year-over-year, with the annual reading at $47.0 million for FY2025, 16.28% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $53.8 million in Q1 2026 for DiaMedica Therapeutics, up from $47.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $53.8 million in Q1 2026 and bottomed at $26.4 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $36.1 million, with a median of $38.0 million recorded in 2024.
  • The largest annual shift saw Shares Outstanding (Weighted Average) increased 0.02% in 2023 before it surged 43.51% in 2024.
  • DiaMedica Therapeutics' Shares Outstanding (Weighted Average) stood at $26.4 million in 2022, then grew by 23.16% to $32.6 million in 2023, then increased by 24.07% to $40.4 million in 2024, then increased by 16.28% to $47.0 million in 2025, then increased by 14.5% to $53.8 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Shares Outstanding (Weighted Average) are $53.8 million (Q1 2026), $47.0 million (Q4 2025), and $45.2 million (Q3 2025).